Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts

Summit Therapeutics' closely watched PD-1xVEGF study surprisingly missed its mark at an interim analysis. Summit's PD-1xVEGF study surprisingly missed its mark at an interim analysis. UCB will pay $2 billion upfront to buy Candid Therapeutics, which has aggregated a group of Chinese assets. J&J eliminated two CD20 CAR-T programs that it licensed from Sino-American biotech AbelZeta. And more. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources…

Source: FiercePharma